Search

everythinglearnresearchcommunity

for

Search:↓

SCUBE3 is a potential hair loss treatment that people are hopeful about. It may provide a solution without the side effects of finasteride.

Maximum serum DHT suppression for finasteride occurs at 8 hours, while for dutasteride, it occurs within 1 to 2 weeks with daily dosing. Dutasteride mesotherapy will be followed by blood tests to check serum DHT changes.

The potential of verteporfin to heal wounds without scarring; however, despite its promising preclinical trials and coverage from a major media outlet, there is still no official clinical trial result and the drug has only garnered attention from hair loss communities.

Clascoterone cream was submitted for review to Health Canada in August 2022, with hopes of approval within 3-6 months. It may potentially enhance finasteride's effects for hair loss treatment.

User asks if washing hair or using hair fibers after minoxidil dries is okay and if dry scalp means full absorption. Some doctors and sources say 50-75% absorption occurs after an hour.

Best future hair loss treatment discussed: verteporfin, kx-826, and GT20029. Verteporfin could potentially end baldness with scarless procedures.

Long-term efficacy of dermarolling with minoxidil is discussed for hair loss treatment. User can't use RU, Fin, or topical Fin due to side effects and considers using finasteride with an aromatase inhibitor as a last resort.

Caffeine liquid may be as effective as Minoxidil for hair loss and could be used together for added benefits. However, the credibility of the research is questionable due to potential bias, as the study was sponsored by a company that sells caffeine solution and was not double-blind.

The conversation is about hair loss treatments and multivitamin recommendations. The user mentions Minoxidil, finasteride, RU58841, biotin, procyanidin B-2, floral oils, and Viviscal.

The user is considering using Tacrolimus Solution and topical Dutasteride to avoid shedding caused by Minoxidil, which they fear may lead to facial side effects. They are also concerned about scalp sensitivity and are exploring different treatment bases to manage seborrheic dermatitis.

Topical dutasteride is suggested as a low side-effect treatment for hair loss, with a proposed dose of 0.025% 1ml/day. It is considered better than finasteride due to its even inhibition of DHT isoforms and lower systemic absorption.

User shared 4 months of hair loss progress using finasteride and minoxidil, noting improved scalp health with the right shampoo. Encouragement from others includes success stories with similar treatments.

A user is considering using redensyl with procapil instead of minoxidil to reduce hair fall. They are stressed about hair loss and seek community feedback on these treatments.

A user is seeking shampoo recommendations for thinning hair that doesn't cause dryness or brittleness. Another user suggests Pura D'or, noting it makes their hair feel better despite thinning, but mentions no shampoo will help with hair loss.

A user is unsure if "Hair Energiser" tablets are effective for hair growth after a year of use. Replies suggest using finasteride instead and call the tablets a scam.

The half-life of Dutasteride is commonly stated as around 5 weeks, but some sources suggest it is 170 hours for men aged 20–49, with further information indicating it varies from 3 days to 5 weeks depending on the dose. The user is seeking clarity on these conflicting figures.

The user has been using dutasteride, lymecycline, betamethasone, and minoxidil for hair loss but struggles with eczema and dry skin. They feel hopeless as no treatments or moisturizers have helped, and they are concerned about their appearance due to their soft facial features.

A user ordered minoxidil online and noticed different packaging, seeking confirmation if it's genuine. Another user confirmed the packaging update, noting it looks the same in both the EU and US.

The conversation discusses the potential of Verteporfin, an FDA-approved drug, for hair loss treatment, particularly in combination with microneedling or PRP. Users express hope and curiosity about its application, while some remain cautious due to the need for more extensive testing.

The conversation lists hair loss treatments including finasteride, dutasteride, RU58841, pyrilutamide, breezula, and fluridil, and suggests ketoconazole as another option. Some users warn against using certain treatments like cyproterone acetate, bicalutamide, and spironolactone due to their strong anti-androgen effects and potential impact on masculinity.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

The potential of using Verteporfin to prevent hair loss scars and possible regrowth, with two doctors currently testing it, although the price of a 15mg bottle is expensive.

Hair loss discussion includes Minoxidil, finasteride, and RU58841 treatments. Hope Medicine has a new CEO, possibly leading to HMI's termination.

The user switched from finasteride to dutasteride for hair loss and saw significant improvement in under two months. They also microneedle, take supplements including collagen and vitamin D3, use ketoconazole shampoo, and noticed accidental hair regrowth with retinol application on their face.

Various methods of using minoxidil, including taking it orally, to treat hair loss. Finasteride is also mentioned as another treatment option.

Ketoconazole is somewhat effective for male pattern baldness (MPB), but the manufacturer promotes it for dandruff instead, possibly because the dandruff market is larger and to avoid confusion among dandruff sufferers without hair loss.

Dutasteride is a stronger 5AR inhibitor than finasteride and can significantly lower DHT levels. Reduced doses of dutasteride may lower side effects.

The conversation discusses the availability of Breezula, a drug for hair loss, now being sold as an acne treatment, and whether it can be applied to the scalp. Users express skepticism about new hair loss treatments and suggest waiting for FDA approval.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.